2026 ICD-10-CM Diagnosis Code E74.05Lysosome-associated membrane protein 2 [LAMP2] deficiency

ICD-10-CM Codes›E00–E89›E70-E88›E74

ICD-10-CM E74.05
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

E74.05 is a billable ICD-10-CM diagnosis code for lysosome-associated membrane protein 2 [LAMP2] deficiency. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified nutritional and metabolic disorders.

Code Identity

ICD-10-CM Code
E74.05
Billable Status
Yes — Valid for Submission
Code Describes
Lysosome-associated membrane protein 2 [LAMP2] deficiency
Short Description
Lysosome-associated membrane protein 2 [LAMP2] deficiency
Same as the full description in the CMS dataset.
Parent Code
E74.0
Glycogen storage disease

Code Classification

ChapterE00–E89Endocrine, nutritional and metabolic diseases
SectionE70-E88Metabolic disorders
CategoryE74Other disorders of carbohydrate metabolism
This CodeE74.05Lysosome-associated membrane protein 2 [LAMP2] deficiency

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Inclusion Terms

  • Danon disease

Code Also

  • , if applicable, associated manifestations such as:
  • dilated cardiomyopathy I42.0
  • obstructive hypertrophic cardiomyopathy I42.1

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • Deficiency, deficient
      • lysosome-associated membrane protein 2 [LAMP2]
    • Disease, diseased
      • Antopol
    • Disease, diseased
      • Danon
    • Disease, diseased
      • glycogen storage
        • lysosomal
          • without acid maltase deficiency
    • Disease, diseased
      • glycogen storage
        • type IIB

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR END016
Other specified and unspecified nutritional and metabolic disorders
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Fanconi Syndrome

    a hereditary or acquired form of generalized dysfunction of the proximal kidney tubule without primary involvement of the kidney glomerulus. it is usually characterized by the tubular wasting of nutrients and salts (glucose; amino acids; phosphates; and bicarbonates) resulting in hypokalemia; acidosis; hypercalciuria; and proteinuria.

  • Glycogen Storage Disease

    a group of inherited metabolic disorders involving the enzymes responsible for the synthesis and degradation of glycogen. in some patients, prominent liver involvement is presented. in others, more generalized storage of glycogen occurs, sometimes with prominent cardiac involvement.

  • Glycogen Storage Disease Type I

    an autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycemia due to lack of glucose production. accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. increased concentrations of lactic acid and hyperlipidemia appear in the plasma. clinical gout often appears in early childhood.

  • Glycogen Storage Disease Type II

    an autosomal recessively inherited glycogen storage disease caused by glucan 1,4-alpha-glucosidase deficiency. large amounts of glycogen accumulate in the lysosomes of skeletal muscle (muscle, skeletal); heart; liver; spinal cord; and brain. three forms have been described: infantile, childhood, and adult. the infantile form is fatal in infancy and presents with hypotonia and a hypertrophic cardiomyopathy (cardiomyopathy, hypertrophic). the childhood form usually presents in the second year of life with proximal weakness and respiratory symptoms. the adult form consists of a slowly progressive proximal myopathy. (from muscle nerve 1995;3:s61-9; menkes, textbook of child neurology, 5th ed, pp73-4)

  • Glycogen Storage Disease Type IIb

    an x-linked dominant multisystem disorder resulting in cardiomyopathy, myopathy and intellectual disability. it is caused by mutation in the gene encoding lysosomal-associated membrane protein 2.

  • Glycogen Storage Disease Type III

    an autosomal recessive metabolic disorder due to deficient expression of amylo-1,6-glucosidase (one part of the glycogen debranching enzyme system). the clinical course of the disease is similar to that of glycogen storage disease type i, but milder. massive hepatomegaly, which is present in young children, diminishes and occasionally disappears with age. levels of glycogen with short outer branches are elevated in muscle, liver, and erythrocytes. six subgroups have been identified, with subgroups type iiia and type iiib being the most prevalent.

  • Glycogen Storage Disease Type IV

    an autosomal recessive metabolic disorder due to a deficiency in expression of glycogen branching enzyme 1 (alpha-1,4-glucan-6-alpha-glucosyltransferase), resulting in an accumulation of abnormal glycogen with long outer branches. clinical features are muscle hypotonia and cirrhosis. death from liver disease usually occurs before age 2.

  • Glycogen Storage Disease Type V

    glycogenosis due to muscle phosphorylase deficiency. characterized by painful cramps following sustained exercise.

  • Glycogen Storage Disease Type VI

    a hepatic glycogen storage disease in which there is an apparent deficiency of hepatic phosphorylase (glycogen phosphorylase, liver form) activity.

  • Glycogen Storage Disease Type VII

    an autosomal recessive glycogen storage disease in which there is deficient expression of 6-phosphofructose 1-kinase in muscle (phosphofructokinase-1, muscle type) resulting in abnormal deposition of glycogen in muscle tissue. these patients have severe congenital muscular dystrophy and are exercise intolerant.

  • Glycogen Storage Disease Type VIII

    an x-linked recessive hepatic glycogen storage disease resulting from lack of expression of phosphorylase-b-kinase activity. symptoms are relatively mild; hepatomegaly, increased liver glycogen, and decreased leukocyte phosphorylase are present. liver shrinkage occurs in response to glucagon.

Code History & ChangesHistory

Replacement E74.05 replaces the following previously assigned code(s):

  • E74.09 - Other glycogen storage disease
FY 2024AddedAdded to the ICD-10-CM code setEffective October 1, 2023.
FY 2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About E74.05Overview

Is E74.05 (Glycogen storage disease) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report lysosome-associated membrane protein 2 [LAMP2] deficiency on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.